Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 RAF around the edges--the paradox of BRAF inhibitors.

Literature DB >> 22256810

RAF around the edges--the paradox of BRAF inhibitors.

Ashani T Weeraratna.

Abstract

Entities: Gene

Mesh：

Substances：

Year: 2012 PMID： 22256810 DOI： 10.1056/NEJMe1111636

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

22 in total

Review 1. Cutaneous toxicities of new treatments for melanoma.

Authors: A Boada; C Carrera; S Segura; H Collgros; P Pasquali; D Bodet; S Puig; J Malvehy
Journal: Clin Transl Oncol Date: 2018-05-24 Impact factor: 3.405

2. Activation by substoichiometric inhibition.

Authors: Melisa Merdanovic; Steven G Burston; Anna Laura Schmitz; Steffen Köcher; Stefan Knapp; Tim Clausen; Markus Kaiser; Robert Huber; Michael Ehrmann
Journal: Proc Natl Acad Sci U S A Date: 2020-01-06 Impact factor: 11.205

3. Mps1 is associated with the BRAF^V600E mutation but does not rely on the classic RAS/RAF/MEK/ERK signaling pathway in thyroid carcinoma.

Authors: Yike Li; Yanyan Zhang; Shuaishuai Xiao; Pengzhou Kong; Caixia Cheng; Ruyi Shi; Fang Wang; Ling Zhang; Juan Wang; Zhiwu Jia; Shuai Wu; Yun Liu; Jiansheng Guo; Xiaolong Cheng; Yongping Cui; Jing Liu
Journal: Oncol Lett Date: 2018-04-24 Impact factor: 2.967

4. Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.

Authors: Ravi K Amaravadi; Kathryn E Hamilton; Xiaohong Ma; Shengfu Piao; Armando Del Portillo; Katherine L Nathanson; Matteo S Carlino; Georgina V Long; Igor Puzanov; Xiaowei Xu; Jennifer J D Morrissette; Kenneth Y Tsai; Keith T Flaherty; Jeffrey A Sosman; Grant R Goodman; Grant A McArthur; Anil K Rustgi; David C Metz; Lynn M Schuchter; Paul B Chapman; Antonia R Sepulveda
Journal: Clin Cancer Res Date: 2015-07-22 Impact factor: 12.531

5. Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.

Authors: N Kramkimel; A Thomas-Schoemann; L Sakji; Jl Golmard; G Noe; E Regnier-Rosencher; N Chapuis; E Maubec; M Vidal; Mf Avril; F Goldwasser; L Mortier; N Dupin; B Blanchet
Journal: Target Oncol Date: 2016-02 Impact factor: 4.493

RAF around the edges--the paradox of BRAF inhibitors.

Review 1. Cutaneous toxicities of new treatments for melanoma.

2. Activation by substoichiometric inhibition.

3. Mps1 is associated with the BRAF^V600E mutation but does not rely on the classic RAS/RAF/MEK/ERK signaling pathway in thyroid carcinoma.

4. Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.

5. Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.

6. Novel insights into the pathogenesis and treatment of NRAS mutant melanoma.

Review 7. [Translational research and diagnostics of melanoma].

Review 8. Vemurafenib-induced progression of breast cancer: a case report and review of the literature.

9. Toward personalized cancer nanomedicine - past, present, and future.

10. Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma.